Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Blood neoplasia·2026
Same author

Low cardiovascular event rates in patients treated with CAR T-cells: Real-world outcomes from two independent cohorts.

ESC heart failure·2026
Same author

IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL.

HemaSphere·2026
Same author

Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidation.

Blood·2026
Same author

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Blood·2026
Same author

KMT2A-rearranged B-lymphoblastic lymphomas are skewed towards a more mature developmental stage.

Leukemia·2026

Related Experiment Video

Updated: May 2, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.3K

R-split-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma.

Stephan Kreher1, Felicitas Lammer, Dieter Augustin

  • 1Department of Hematology, Oncology and Tumor Immunology, Charite Universitätsmedizin Berlin, Berlin, Germany.

European Journal of Haematology
|March 12, 2014
PubMed
Summary

Elderly patients with diffuse large B-cell lymphoma can receive full-dose chemoimmunotherapy using a modified R-CHOP regimen (R-split-CHOP). This approach aims to reduce complications in older adults, showing promising survival rates.

Keywords:
DLBCLR-CHOPR-split-CHOPelderlyrituximab

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Related Experiment Videos

Last Updated: May 2, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

9.2K

Area of Science:

  • Oncology
  • Hematology
  • Clinical Pharmacology

Background:

  • Standard chemoimmunotherapy for diffuse large B-cell lymphoma (DLBCL) is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone).
  • Elderly patients with DLBCL often face increased treatment-related complications due to comorbidities, complicating standard R-CHOP administration.

Purpose of the Study:

  • To evaluate the safety and efficacy of a modified R-CHOP regimen in elderly patients with DLBCL.
  • To assess if splitting the administration of cyclophosphamide and doxorubicin over two days (R-split-CHOP) can reduce treatment-related complications in this population.

Main Methods:

  • Retrospective analysis of 30 newly diagnosed DLBCL patients treated with R-split-CHOP.
  • Full-dose R-CHOP regimen with cyclophosphamide and doxorubicin administered over two days to reduce peak plasma levels.

Main Results:

  • An overall response rate of 87% was observed.
  • Three-year overall survival probability was 60.6%, and progression-free survival was 49.7%.
  • Grade 3/4 infectious complications occurred in 30% of patients, with no treatment-related deaths.

Conclusions:

  • R-split-CHOP is a potentially valuable option for safely delivering full-dose R-CHOP to elderly DLBCL patients.
  • This modified regimen may mitigate treatment-related complications in older individuals at risk.